An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

Yukinari Kato; Tomokazu Ohishi; Junko Takei; Takuro Nakamura; Masato Sano; Teizo Asano; Yusuke Sayama; Hideki Hosono; Manabu Kawada; Mika K. Kaneko

doi:10.1089/mab.2020.0009

An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

Yukinari Kato, Tomokazu Ohishi, Junko Takei, Takuro Nakamura, Masato Sano, Teizo Asano, Yusuke Sayama, Hideki Hosono, Manabu Kawada, Mika K. Kaneko

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.

Original language	English
Pages (from-to)	123-128
Number of pages	6
Journal	Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Volume	39
Issue number	4
DOIs	https://doi.org/10.1089/mab.2020.0009
Publication status	Published - 2020 Aug 1

Keywords

antitumor activity
HER2
monoclonal antibody

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/mab.2020.0009

Cite this

Kato, Y., Ohishi, T., Takei, J., Nakamura, T., Sano, M., Asano, T., Sayama, Y., Hosono, H., Kawada, M., & Kaneko, M. K. (2020). An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 39(4), 123-128. https://doi.org/10.1089/mab.2020.0009

@article{a739a0d4c2364493b5debcf500d84345,

title = "An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts",

abstract = "Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.",

keywords = "antitumor activity, HER2, monoclonal antibody",

author = "Yukinari Kato and Tomokazu Ohishi and Junko Takei and Takuro Nakamura and Masato Sano and Teizo Asano and Yusuke Sayama and Hideki Hosono and Manabu Kawada and Kaneko, {Mika K.}",

note = "Funding Information: This research was supported in part by AMED under Grant Numbers JP20am0401013 (Y.K.), JP20am0101078 (Y.K.), and JP20ae0101028 (Y.K.), and by JSPS KAKENHI Grant Numbers 17K07299 (M.K.K.) and 19K07705 (Y.K.). Publisher Copyright: {\textcopyright} Copyright 2020, Mary Ann Liebert, Inc., publishers 2020.",

year = "2020",

month = aug,

day = "1",

doi = "10.1089/mab.2020.0009",

language = "English",

volume = "39",

pages = "123--128",

journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",

issn = "2167-9436",

publisher = "Mary Ann Liebert Inc.",

number = "4",

}

Kato, Y, Ohishi, T, Takei, J, Nakamura, T, Sano, M, Asano, T , Sayama, Y, Hosono, H, Kawada, M & Kaneko, MK 2020, 'An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts', Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, vol. 39, no. 4, pp. 123-128. https://doi.org/10.1089/mab.2020.0009

TY - JOUR

T1 - An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

AU - Kato, Yukinari

AU - Ohishi, Tomokazu

AU - Takei, Junko

AU - Nakamura, Takuro

AU - Sano, Masato

AU - Asano, Teizo

AU - Sayama, Yusuke

AU - Hosono, Hideki

AU - Kawada, Manabu

AU - Kaneko, Mika K.

N1 - Funding Information: This research was supported in part by AMED under Grant Numbers JP20am0401013 (Y.K.), JP20am0101078 (Y.K.), and JP20ae0101028 (Y.K.), and by JSPS KAKENHI Grant Numbers 17K07299 (M.K.K.) and 19K07705 (Y.K.). Publisher Copyright: © Copyright 2020, Mary Ann Liebert, Inc., publishers 2020.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.

AB - Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.

KW - antitumor activity

KW - HER2

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85089809337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089809337&partnerID=8YFLogxK

U2 - 10.1089/mab.2020.0009

DO - 10.1089/mab.2020.0009

M3 - Article

C2 - 32552424

AN - SCOPUS:85089809337

SN - 2167-9436

VL - 39

SP - 123

EP - 128

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

IS - 4

ER -

An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this